問題一覧
1
1, 3, and 4 only
2
2, 3, and 4 only
3
1, 2, and 3 only
4
1, 2, and 4 only
5
Pharmacokinetic
6
Use of a fully ionized drug
7
Atropine
8
0.6
9
Pharmacodynamic
10
1, 2, and 3 only
11
Norepinephrine
12
Adrenergic
13
M3
14
Adrenergic bronchodilators
15
Albuterol
16
Formoterol
17
25 mcg/puff
18
2 puffs every 12 hr
19
Treatment of reversible airflow obstruction
20
1, 2, and 3 only
21
Rescue
22
Catechol O-methyltransferase (COMT)
23
Racemic epinephrine
24
4 to 6 hr
25
1, 2, and 4 only
26
Indacaterol
27
Brovana
28
2, 3, and 4 only
29
1, 2, and 3 only
30
1 and 2 only
31
17 mcg/puff
32
2 puffs four times daily
33
4 to 6 hr
34
4 to 6 hr
35
I-neb
36
Cough and dry mouth
37
1, 2, and 4 only
38
2, 3, and 4 only
39
1, 2, and 3 only
40
Reduce dose to 1 to 2 breaths per session and then gradually increase to 3.
41
Substituting its sulfhydryl group for disulfide bonds and breaking a portion of the bond forming the gel structure
42
Administration of adrenergic bronchodilator
43
1, 3, and 4 only
44
Right-to-left shunt dependence
45
2, 3, and 4 only
46
expectorants
47
1, 2, and 3 only
48
Less than 25%
49
Maintenance of mild to moderate persistent asthma
50
250 mcg/puff
51
1 and 3 only
52
800 mcg
53
Ciclesonide
54
Use of anticholinergics
55
1, 2, and 3 only
56
Inhibits degranulation of mast cells.
57
1 and 2 only
58
Leukotriene modifiers
59
1, 2, and 3 only
60
Pneumocystis jiroveci
61
1, 2, and 3 only
62
1, 3, and 4 only
63
1, 2, 3, and 5 only
64
1, 3, and 4 only
65
Influenza
66
It relaxes vascular smooth muscle by binding to the heme group of cystolic guanylate, activating guanylate cyclase, increasing cyclic GMP.
67
1 and 3 only
68
Suspension of liquid or solid particles in a gas
69
1, 2, and 4 only
70
Output
71
Emitted dose
72
Cascade impaction
73
Mean mass aerodynamic diameter (MMAD)
74
GSD
75
Heterodisperse
76
Deposition
77
1, 2, and 3 only
78
Inertial impaction
79
2 and 3 only
80
Upper airways
81
Sedimentation
82
Central airways
83
10-sec breath-hold
84
Brownian diffusion
85
Most are cleared during exhalation.
86
MMAD of 0.1 μm
87
Alveoli
88
5 to 50 μm
89
2 to 5 μm
90
Less than 1 μm
91
Aging
92
The rate of particle growth is directly proportional to particle size.
93
Increase in size because of the absorption of molecular water.
94
Adverse drug reactions
95
1, 2, and 3
96
1, 3, and 4 only
97
1, 2, 3, and 4
98
Add coughing and postural drainage to the therapy.
99
Spinning disk nebulizers
100
Metered dose inhaler
ch. 2
ch. 2
Darya Rose · 83問 · 2年前ch. 2
ch. 2
83問 • 2年前ch. 3
ch. 3
Darya Rose · 88問 · 2年前ch. 3
ch. 3
88問 • 2年前ch 41
ch 41
Darya Rose · 78問 · 2年前ch 41
ch 41
78問 • 2年前ch 42
ch 42
Darya Rose · 96問 · 2年前ch 42
ch 42
96問 • 2年前ch 4
ch 4
Darya Rose · 86問 · 2年前ch 4
ch 4
86問 • 2年前ch. 6
ch. 6
Darya Rose · 93問 · 2年前ch. 6
ch. 6
93問 • 2年前ch. 39
ch. 39
Darya Rose · 111問 · 2年前ch. 39
ch. 39
111問 • 2年前ch. 5
ch. 5
Darya Rose · 95問 · 2年前ch. 5
ch. 5
95問 • 2年前ch. 5
ch. 5
Darya Rose · 41問 · 2年前ch. 5
ch. 5
41問 • 2年前ch. 7
ch. 7
Darya Rose · 22問 · 2年前ch. 7
ch. 7
22問 • 2年前ch. 6
ch. 6
Darya Rose · 93問 · 2年前ch. 6
ch. 6
93問 • 2年前ch. 7
ch. 7
Darya Rose · 96問 · 2年前ch. 7
ch. 7
96問 • 2年前ch. 44
ch. 44
Darya Rose · 94問 · 2年前ch. 44
ch. 44
94問 • 2年前ch. 8
ch. 8
Darya Rose · 86問 · 2年前ch. 8
ch. 8
86問 • 2年前ch. 43
ch. 43
Darya Rose · 65問 · 2年前ch. 43
ch. 43
65問 • 2年前ch. 9
ch. 9
Darya Rose · 100問 · 2年前ch. 9
ch. 9
100問 • 2年前ch. 19 / 14
ch. 19 / 14
Darya Rose · 53問 · 2年前ch. 19 / 14
ch. 19 / 14
53問 • 2年前ch. 10
ch. 10
Darya Rose · 90問 · 2年前ch. 10
ch. 10
90問 • 2年前ch. 21
ch. 21
Darya Rose · 47問 · 2年前ch. 21
ch. 21
47問 • 2年前問題一覧
1
1, 3, and 4 only
2
2, 3, and 4 only
3
1, 2, and 3 only
4
1, 2, and 4 only
5
Pharmacokinetic
6
Use of a fully ionized drug
7
Atropine
8
0.6
9
Pharmacodynamic
10
1, 2, and 3 only
11
Norepinephrine
12
Adrenergic
13
M3
14
Adrenergic bronchodilators
15
Albuterol
16
Formoterol
17
25 mcg/puff
18
2 puffs every 12 hr
19
Treatment of reversible airflow obstruction
20
1, 2, and 3 only
21
Rescue
22
Catechol O-methyltransferase (COMT)
23
Racemic epinephrine
24
4 to 6 hr
25
1, 2, and 4 only
26
Indacaterol
27
Brovana
28
2, 3, and 4 only
29
1, 2, and 3 only
30
1 and 2 only
31
17 mcg/puff
32
2 puffs four times daily
33
4 to 6 hr
34
4 to 6 hr
35
I-neb
36
Cough and dry mouth
37
1, 2, and 4 only
38
2, 3, and 4 only
39
1, 2, and 3 only
40
Reduce dose to 1 to 2 breaths per session and then gradually increase to 3.
41
Substituting its sulfhydryl group for disulfide bonds and breaking a portion of the bond forming the gel structure
42
Administration of adrenergic bronchodilator
43
1, 3, and 4 only
44
Right-to-left shunt dependence
45
2, 3, and 4 only
46
expectorants
47
1, 2, and 3 only
48
Less than 25%
49
Maintenance of mild to moderate persistent asthma
50
250 mcg/puff
51
1 and 3 only
52
800 mcg
53
Ciclesonide
54
Use of anticholinergics
55
1, 2, and 3 only
56
Inhibits degranulation of mast cells.
57
1 and 2 only
58
Leukotriene modifiers
59
1, 2, and 3 only
60
Pneumocystis jiroveci
61
1, 2, and 3 only
62
1, 3, and 4 only
63
1, 2, 3, and 5 only
64
1, 3, and 4 only
65
Influenza
66
It relaxes vascular smooth muscle by binding to the heme group of cystolic guanylate, activating guanylate cyclase, increasing cyclic GMP.
67
1 and 3 only
68
Suspension of liquid or solid particles in a gas
69
1, 2, and 4 only
70
Output
71
Emitted dose
72
Cascade impaction
73
Mean mass aerodynamic diameter (MMAD)
74
GSD
75
Heterodisperse
76
Deposition
77
1, 2, and 3 only
78
Inertial impaction
79
2 and 3 only
80
Upper airways
81
Sedimentation
82
Central airways
83
10-sec breath-hold
84
Brownian diffusion
85
Most are cleared during exhalation.
86
MMAD of 0.1 μm
87
Alveoli
88
5 to 50 μm
89
2 to 5 μm
90
Less than 1 μm
91
Aging
92
The rate of particle growth is directly proportional to particle size.
93
Increase in size because of the absorption of molecular water.
94
Adverse drug reactions
95
1, 2, and 3
96
1, 3, and 4 only
97
1, 2, 3, and 4
98
Add coughing and postural drainage to the therapy.
99
Spinning disk nebulizers
100
Metered dose inhaler